Amneal Pharmaceuticals (AMRX) Receivables (2017 - 2026)

Amneal Pharmaceuticals' Receivables history runs 10 years deep, the most recent figure standing at $6.7 million for Q1 2026.

• In Q1 2026, Receivables rose 170.93% year-over-year to $6.7 million; the TTM figure through Mar 2026 stood at $6.7 million (up 170.93% YoY), while the FY2025 annual figure was $5.3 million, down 99.32% from the prior year.
• Receivables was $6.7 million for Q1 2026 at Amneal Pharmaceuticals, up from $5.3 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $1.4 billion in Q2 2025 to a low of $2.3 million in Q4 2022.
• Historically, Receivables has averaged $679.7 million across 5 years, with a median of $777.6 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Receivables slumped 99.81% in 2022, then surged 52345.12% in 2023.
• A 5-year view of Receivables shows it stood at $2.3 million in 2022, then soared by 52345.12% to $1.2 billion in 2023, then slumped by 35.73% to $777.6 million in 2024, then tumbled by 99.32% to $5.3 million in 2025, then increased by 26.0% to $6.7 million in 2026.
• The last three Receivables figures came in at $6.7 million (Q1 2026), $5.3 million (Q4 2025), and $909.4 million (Q3 2025), per Business Quant data.